5 hours ago
1
AlexSecret
Cogent Biosciences (NASDAQ:COGT) surged ~31% Monday after releasing positive mid-stage data on bezuclastinib, its candidate for non-advanced systemic mastocytosis.
Bezuclastinib met its primary endpoint, a highly statistically significant difference in the mean change in total symptom score (TSS) at 24 weeks versus placebo. Participants
English (US) ·